Effects of CD3McAb and rhIL-2 activated bone marrow on the killing and purging of leukemia cells

• Published in: Genetics and molecular research 2015-12, Vol.14 (4), p.18287-18292
• Main Authors: Wei, X C, Yang, D D, Han, X R, Zhao, Y A, Li, Y C, Zhang, L J, Wang, J J
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacology; Bone Marrow Cells - drug effects; Bone Marrow Cells - metabolism; Bone Marrow Cells - pathology; Bone Marrow Purging - methods; Bone Marrow Transplantation; CD3 Complex - immunology; CD3 Complex - metabolism; Cell Line, Tumor; Cell Survival - drug effects; Colony-Forming Units Assay; Female; Granulocyte-Macrophage Progenitor Cells; HL-60 Cells; Humans; Immunophenotyping; Interleukin-2 - pharmacology; K562 Cells; Leukemia - metabolism; Leukemia - pathology; Leukemia - therapy; Male; Middle Aged; Phenotype; Young Adult
• ISSN: 1676-5680; 1676-5680
• DOI: 10.4238/2015.December.23.16

We investigated the roles of CD3McAb and rhIL-2 activated bone marrow in the killing and purging of leukemia cells. Cytotoxicity of activated bone marrow was detected with MTT assay. CFU-GM level in activated bone marrow and the destruction of leukemia cells were measured using the semi-solid cell culture. Immune activation markers in activated bone marrow were detected by indirect immunofluorescence assay. Bone marrow activated by CD3McAb and rhIL-2 displayed significantly upregulated the killing and purging abilities on the leukemia cell line K562 and HL-60. Such effects were superior to that of bone marrow activated by rhIL-2 or CD3McAb alone (P < 0.05, P < 0.01). Activation by rhIL-2 and (or) CD3McAb exerted no obvious influence on CFU-GM level in bone marrow. Compared with bone marrow activated by rhIL-2 or CD3McAb alone, the synergistic effect of both CD3McAb+ and hIL-2 caused significant increase of CD3(+), CD8(+), CD19(+), CD25(+), CD38(+), and CD56(+) levels. Our study indicates that CD3McAb enhanced the killing and purging effects of rhIL-2 activated bone marrow on leukemia cells.